Latest News of JNJ
With 73% ownership of the shares, Johnson & Johnson (NYSE:JNJ) is heavily dominated by institutional owners
By Yahoo! Finance |
2 weeks ago
Analyzing ownership and analyst forecasts of a stock like Johnson & Johnson (NYSE:JNJ) can reveal investment opportunities. Institutional investors, holding 73% ownership, have significant influence d...
Is Johnson & Johnson (JNJ) the Best Pharma Stock to Buy Right Now?
By Yahoo! Finance |
2 weeks ago
The pharmaceutical industry, valued at $516.48 billion, is rapidly growing with advancements in medical technology and treatments. Companies like Johnson & Johnson and Roche are investing in research ...
Top Stock Reports for Amazon.com, Johnson & Johnson and Boston Scientific
By Yahoo! Finance |
3 weeks ago
Zacks Research Daily on October 30, 2024, covers Amazon, Johnson & Johnson, Boston Scientific, and Armanino Foods. The reports highlight financial performance, industry trends, and growth opportunitie...
-
Johnson & Johnson's Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body's Smaller Areas
By Yahoo! Finance | 3 weeks agoJohnson & Johnson reported positive results from the Phase 3b SPECTREM study on Tremfya for moderate plaque psoriasis, showing significant skin clearance and treatment outcomes. Tremfya achieved highe...
-
Johnson & Johnson (JNJ): Legal Challenges Over Talc Products Impact Dow Performance
By Yahoo! Finance | 3 weeks agoThe article discusses the performance of Johnson & Johnson and other worst-performing Dow stocks in 2022. It highlights market resilience, potential buying opportunities, impact of elections and Fed r...
-
If You Invested $10,000 In Johnson & Johnson Stock 10 Years Ago, How Much Would You Have Now?
By Yahoo! Finance | 4 weeks agoJohnson & Johnson, a global healthcare company, is set to report Q4 2024 earnings. Stock value increased from $100 to $162.83 over 10 years with dividends totaling $3,739, resulting in a total return ...
-
Decoding Johnson & Johnson (JNJ): A Strategic SWOT Insight
By Yahoo! Finance | 4 weeks agoJohnson & Johnson (NYSE: JNJ) reported its financial performance post divesting its consumer business, Kenvue. The focus is on its strong pharmaceutical division, investing in key therapeutic areas an...
-
Johnson & Johnson's (NYSE:JNJ) investors will be pleased with their favorable 45% return over the last five years
By Yahoo! Finance | 4 weeks agoInvesting for the long term aims to generate profit, ideally exceeding market averages. While Johnson & Johnson's share price has seen a 26% rise in 5 years, its EPS growth of 2.9% indicates higher ma...
-
Johnson & Johnson (JNJ): Growth Prospects Enhanced by Key Acquisitions and Approvals
By Yahoo! Finance | 1 month agoThe article explores the top medical stocks to invest in, with Johnson & Johnson ranking 5th. The medical industry is projected to grow, especially in sectors like hospitals and pharmaceuticals. Hedge...
-
Pharma Stock Roundup: JNJ's Q3 Earnings, FDA Nod to Some New Drugs
By Yahoo! Finance | 1 month agoJohnson & Johnson kicked off the third-quarter earnings season in the drug and biotech sector. Pfizer, Roche, and AbbVie received FDA approval for new drugs. Sanofi plans to sell a 50% stake in its co...
-
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug
By Yahoo! Finance | 1 month agoBofA Securities upgraded Tyra Biosciences, a biotech company focusing on precision medicines. Tyra-300 showed promising preclinical results in hypochondroplasia. BofA raised the stock rating to Buy wi...
-
ETFs in Focus Post JNJ Q3 Earnings Beat, Target Price Hike
By Yahoo! Finance | 1 month agoJohnson & Johnson's strong Q3 earnings brought optimism to the healthcare sector. Analysts raised target prices, reflecting growth prospects....
-
Deloitte, Johnson & Johnson execs say people aren't using their health benefits until they are in crisis
By Yahoo! Finance | 1 month agoOver 130 million Americans live with chronic conditions, with mental health issues affecting all generations. Health equity is crucial, especially for marginalized groups. Leaders emphasize the import...
-
Q3 Earnings Beats: C, GS, BAC, JNJ, WBA; Empire State Lower
By Yahoo! Finance | 1 month agoThe Q3 earnings season is gaining momentum with Wall Street banks reporting strong results. Citigroup, Goldman Sachs, Bank of America, Johnson & Johnson, and Walgreens Boots Alliance announce positive...
-
Johnson & Johnson (JNJ) Tops Q3 Earnings and Revenue Estimates
By Yahoo! Finance | 1 month agoJohnson & Johnson reported earnings of $2.42 per share, surpassing estimates. Their revenue also exceeded expectations. The company's stock performance and future outlook will depend on earnings guida...